mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 111, Issue 47, Pages E5076-E5085
Publisher
Proceedings of the National Academy of Sciences
Online
2014-11-11
DOI
10.1073/pnas.1407104111
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting TOR dependence in cancer
- (2015) Oncotarget
- Requirement for Rictor in homeostasis and function of mature B lymphoid cells
- (2013) K. Lee et al. BLOOD
- B Cell-Specific Deficiencies in mTOR Limit Humoral Immune Responses
- (2013) S. Zhang et al. JOURNAL OF IMMUNOLOGY
- The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus
- (2013) Rachael Keating et al. NATURE IMMUNOLOGY
- Regulation of Immune Responses by mTOR
- (2012) Jonathan D. Powell et al. Annual Review of Immunology
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- p110 Phosphoinositide 3-Kinase Represses IgE Switch by Potentiating BCL6 Expression
- (2012) T.-t. Zhang et al. JOURNAL OF IMMUNOLOGY
- Inhibition of Mechanistic Target of Rapamycin Promotes Dendritic Cell Activation and Enhances Therapeutic Autologous Vaccination in Mice
- (2012) E. Amiel et al. JOURNAL OF IMMUNOLOGY
- Akt and mTOR in B Cell Activation and Differentiation
- (2012) Jose J. Limon et al. Frontiers in Immunology
- mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment
- (2011) Q. Jiang et al. CANCER RESEARCH
- AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias
- (2011) Stephen M. Sykes et al. CELL
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
- (2011) Seth A. Wander et al. JOURNAL OF CLINICAL INVESTIGATION
- The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
- (2011) L Willems et al. LEUKEMIA
- Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program
- (2011) Peter J. Houghton et al. PEDIATRIC BLOOD & CANCER
- Phosphoinositide 3-Kinase Activity in T Cells Regulates the Magnitude of the Germinal Center Reaction
- (2010) J. Rolf et al. JOURNAL OF IMMUNOLOGY
- mTORC1 controls fasting-induced ketogenesis and its modulation by ageing
- (2010) Shomit Sengupta et al. NATURE
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
- (2010) Matthew R Janes et al. NATURE MEDICINE
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Immune Regulation by Rapamycin: Moving Beyond T Cells
- (2009) M. R. Janes et al. Science Signaling
- Genetic or pharmaceutical blockade of p110δ phosphoinositide 3-kinase enhances IgE production
- (2008) Ting-ting Zhang et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation
- (2008) Hart S Dengler et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started